Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.

被引：0
|
作者：
Ulahannan, Susanna Varkey
Johnson, Melissa Lynne
Weiss, Mia C.
Vandross, Andrae L.
Vidal-Cardenas, Sofia Luz
Syed, Mustafa
Tolcher, Anthony W.
机构：
[1] Univ Okahoma Hlth Sci Ctr, Oklahoma City, OK USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] NEXT Oncol, Austin, TX USA
[5] Exelixis Inc, Alameda, CA USA
[6] NEXT Oncol, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-2494-5577-2829-12292; 613-135-244-3829-325; 3282-3306-2666-3910; 283-324; 613-4678-146-3542; 261-436; 3282-4644-9184; 6; 3; 2;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS237
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS237 / TPS237
页数：1
相关论文
共 28 条
  • [1] Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.
    Ulahannan, Susanna Varkey
    Johnson, Melissa Lynne
    Weiss, Mia C.
    Vandross, Andrae L.
    Vidal-Cardenas, Sofia Luz
    Syed, Mustafa
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS421 - TPS421
  • [2] Phase I study of the tissue factor-targeting antibody-drug conjugate XB002 among patients with advanced solid tumors (JEWEL-101): Design of expansion cohorts for endometrial, epithelial ovarian, and cervical cancers
    Syed, Mustafa
    Tolcher, Anthony
    Johnson, Melissa
    Weiss, Mia
    Vandross, Andrae
    Vidal-Cardenas, Sofia
    Ulahannan, Susanna
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S280 - S280
  • [3] Phase 1 study of the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): Design of the triple-negative and hormone receptor-positive breast cancer expansion cohorts
    Ulahannan, Susanna
    Johnson, Melissa
    Weiss, Mia
    Vandross, Andrae
    Vidal-Cardenas, Sofia
    Syed, Mustafa
    Tolcher, Anthony
    CANCER RESEARCH, 2024, 84 (09)
  • [4] A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage
    Ulahannan, S.
    Johnson, M. L.
    Park, H.
    Vandross, A.
    Uttamsingh, S.
    Li, J.
    Syed, M.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S92 - S93
  • [5] Phase I expansion study of the tissue factor (TF)etargeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
    Ulahannan, S.
    Johnson, M. L.
    Weiss, M. C.
    Vandross, A.
    Vidal-Cardenas, S.
    Syed, M.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1500 - S1501
  • [6] Phase 1 Study of the Tissue Factor Targeting Antibody-Drug Conjugate XBOO2 in Patients with Advanced Solid Tumors (JEWEL-101): Design of Expansion Cohorts for Squamous Cell Carcinoma of the Head and Neck
    Ulahannan, S.
    Johnson, M.
    Weiss, M.
    Vandross, A.
    Vidal-Cardenas, S.
    Syed, M.
    Tolcher, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E31 - E32
  • [7] A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
    Danila, Daniel Costin
    Szmulewitz, Russell Zelig
    Baron, Ari David
    Higano, Celestia S.
    Scher, Howard I.
    Morris, Michael J.
    Gilbert, Houston
    Brunstein, Flavia
    Lemahieu, Vanessa
    Kabbarah, Omar
    Fine, Bernard M.
    Maslyar, Daniel J.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
    Danila, Daniel C.
    Szmulewitz, Russell Z.
    Vaishampayan, Ulka
    Higano, Celestia S.
    Baron, Ari D.
    Gilbert, Houston N.
    Brunstein, Flavia
    Milojic-Blair, Marija
    Wang, Bei
    Kabbarah, Omar
    Mamounas, Michael
    Fine, Bernard M.
    Maslyar, Daniel J.
    Ungewickell, Alexander
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (36) : 3518 - +
  • [9] Lorigerlimab, a bispecific PD-13CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.
    Luke, Jason J.
    Sharma, Manish
    Chandana, Sreenivasa R.
    Lugowska, Iwona A.
    Szczylik, Cezary
    Zolnierek, Jakub
    Cote, Gregory Michael
    Mantia, Charlene
    Dziadziuszko, Rafal
    Sanborn, Rachel E.
    Casey, Denise
    Long, Lori
    Ward, Ashley
    Kaminker, Patrick
    James, Angela Joubert
    Di Pucchio, Tiziana
    Cybulska-Stopa, Bozena
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)
    Aggarwal, Rahul Raj
    Vuky, Jacqueline
    VanderWeele, David James
    Rettig, Matthew
    Heath, Elisabeth I.
    Beer, Tomasz M.
    Huang, Jiaoti
    Pawlowska, Nela
    Sinit, Ryan
    Abbey, Jill
    Liu, Bin
    Nasoff, Marc
    Dorr, Andrew
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
123